Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Efectin, Venaxibene, Venladoz, Venlafab, Venlafaxin; Belgium: Efexor, Venlafaxine, Vennaxa; Bulgaria: Deprexor, Laroxin, Venlagamma; Czech Republic: Argofan, Convalemin, Depant Prolong, Efectin, Elify, Faxiprol, Lafaxon, Mollome, Nisaxin, Nopekar, Olwexya, Prefaxine, Ranfaxiran, Tifaxin, Velaxin, Venlafab, Venlafaxin, Venlagamma; Denmark: Efexor, Venlafaxin; Estonia: Alventa, Arfogan, Efexor, Lanvexin, Venlafaxin, Venlagamma, Venlobax; Finland: Efexor, Venlafaxin; France: Effexor, Venlafaxine; Germany: Kirlaven, Lindalex, Lunaven, Tonpular, Trevilor, Vandral, Venla, Venlabeta, VenlaCare, Venlafaxin, Venlagab, Venlagamma, Venlanira, Venlasan, Venlastad, Venlatrev; Greece: Arvifax, Azanta, Deprevix, Efaxin, Efexor, Elify, Livexor, Melocin, Memomax, Norafexine, Norezor, Rodomel, Serosmine, Tudor, Vefaxine, Velept, Velpine, Ven-Fax, Venaxol, Venfaxil, Venlafaxine, Venlasan, Voxafen, Xadevil; Hungary: Arixen, Aveksin, Denegis, Falven, Faxinev, Faxiprol, Fobiven, Jarvis, Nopekar, Olwexya, Tavex, Velaxin, Venlafaxin, Venlagamma, Venlaran, Venlaxgen, Ventadepress; Ireland: Efaxil, Efexor, Ireven, Tonpular, Vedixal, Velexor, Venlafaxine, Venlift, Venlofex, Vensir; Italy: Efexor; Lithuania: Alventa, Argofan, Efexor, Elify, Lanvexin, Prefaxine, Velaxin, Venlafaxin, Venlagamma, Venlobax; Luxembourg: Efexor; Netherlands: Elbfaxin, Efexor, Hafaxin, Jarvis, Venlaburg, Venlafaxine, Vendep, Venfalex, Venlabacher, Venladem, Venladoz, Venlanofi, Venlaraf, Venlasand, Venlatif, Venlexor; Poland: Agrofan, Alventa, Axyven, Efectin, Enlaf, Faxigen, Faxolet, Jarvis, Lafactin, Paxifar, Prefaxine, Symfaxin, Tavex, Tifaxin, Velafax, Velaxin, Velaxiran, Venlabax, Venlafaxin, Venlafaxinum, Venlalek, Venlax, Venlectine, Xaveksin; Portugal: Desinax, Efexor, Genexin, Leritex, Pracet, Venlafaxina, Venxin, Xapnev, Zarelix; Romania: Adoxa EP, Alventa, Argofan, Efectin, Elify, Fobiless, Ivryx, Jarvis, Nopekar, Posipres, Velaxin, Venlafaxina, Venlafaxine, Venlagamma; Slovakia: Alventa, Argofan, Depant, Efectin, Elify, Faxiprol, Mollome, Nopekar, Prefaxine, Ranfaxiran, Tifaxin, Velafax, Velaxin, Venlafaxin, Venlagamma, Voxatin; Slovenia: Alventa, Efectin, Efexiva, Faxiprol, Venlafaksin, Venlagamma; Spain: Dobupal, Vandral, Velahibin, Venlabrain, Venlafaxina; Sweden: Durnit-Liconsa, Efexor, Trevilor, Venette, Venlafaxin, Venlanidda; UK: Bonilux, Efexor, Foraven, Politid, Venlafaxine, ViePax, Winfex.

North America

Canada: Effexor, Venlafaxine; USA: Effexor, Venlafaxine.

Latin America

Argentina: Efexor, Elafax, Ganavax, Mezine, Pramina, Quilarex, Sesarén, Venlafaxina; Brazil: Efexor, Novidat, Venlafaxina, Venlaxin, Venlift; Mexico: Benolaxe, Efexor, Odvén.

Drug combinations


Venlafaxine Hydrochloride: C~17~H~27~NO~2~ HCl. Mw: 313.86. (1) Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride; (2)(±)-1-[α-[(Dimethylamino)methyl]-p-methoxybenzyl]cyclohexanol hydrochloride. CAS-99300-78-4; CAS-93413-69-5 (venlafaxine)(1989).

Pharmacologic Category

Antidepressants; Selective Serotonin- and Norepinephrine-reuptake Inhibitors. (ATC-Code: N06AX16).

Mechanism of action

Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake.

Therapeutic use

Treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder (social phobia), panic disorder.

Pregnancy and lactiation implications

Venlafaxine and its active metabolite ODV cross human placenta. Neonatal seizures and neonatal abstinence syndrome noted in case reports following maternal use of venlafaxine during pregnancy. Nonteratogenic effects in newborn following SSRI/SNRI exposure late in 3^rd^ trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hyper- or hypotonia, hyperreflexia, jitteriness, irritability, constant crying, and tremor. Venlafaxine and ODV found in human milk. Should be prescribed to breast-feeding mother only when benefits outweigh potential risks.

Unlabeled use

Obsessive-compulsive disorder. Hot flushes. Neuropathic pain. Attention-deficit hyperactivity disorder.


Hypersensitivity to venlafaxine or any component of the formulation. Use of MAOIs within 14 days.

Warnings and precautions

Antidepressants increase risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. Venlafaxine not FDA approved for use in children. Possibility of suicide attempt inherent in major depression and may persist until remission occurs. May worsen psychosis in some patients or precipitate shift to mania or hypomania in bipolar disorder. Monotherapy in bipolar disorder should be avoided. Venlafaxine not FDA approved for treatment of bipolar depression. May cause increase in anxiety, nervousness, and insomnia. May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin or NSAIDs due to ulcerogenic potential. Has low potential to cause CNS depression. May cause hypercholesterolemia. Dose-related increases in systolic and diastolic blood pressure documented. Interstitial lung disease and eosinophilic pneumonia rarely reported (may present as progressive dyspnea, cough, and/or chest pain). May cause or exacerbate sexual dysfunction. SSRIs and SNRIs associated with development of SIADH. Hyponatremia reported rarely (including severe cases with serum sodium <110 mmol/L), predominately in the elderly. Dose-dependent weight loss observed in both pediatric and adult patients. May cause sustained increase in blood pressure or tachycardia (use caution in recent history of myocardial infarction, unstable heart disease, or hyperthyroidism). Use caution in hepatic and renal impairment (clearance decreased and plasma concentrations increased). May cause mydriasis (use caution in increased intraocular pressure or risk of acute narrow-angle glaucoma). Use caution with previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism. Use caution with concomitant use of NSAIDs, ASA, or other drugs which affect coagulation (risk of bleeding may be potentiated). Concurrent use with MAOIs contraindicated (potential for serotonin syndrome). Do not begin venlafaxine within 14 days of terminating MAOI therapy. Do not initiate MAOI treatment within 7 days of discontinuing venlafaxine. Serotonin syndrome (e.g. symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia) may occur with concomitant proserotonergic drugs (i.e. SSRIs/SNRIs or triptans) or agents which reduce metabolism of venlafaxine. Concurrent use of serotonin precursors (e.g. tryptophan) not recommended. Agents causing weight loss or anorectic effects should be avoided. Not FDA approved for use in children. May increase risks associated with electroconvulsive therapy. Withdrawal syndrome might occur upon abrupt discontinuation or dosage reduction.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart